All In Biotech

Drug Trial Radar · NCT06940791

Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)

Tirabrutinib Maintenance Versus Placebo in Patients With Primary Central Nervous System Lymphoma in Complete Remission: a Randomized Phase II Study (JCOG2104)

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Oct 6, 2023

Primary completion

Feb 2030

Study completion Feb 2030

Sponsor

Lead sponsor
Kyorin UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Center, Japan; Ono Pharmaceutical Co., Ltd.; Japan Clinical Oncology Group
First posted
Apr 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A double-blind, randomized phase II comparative trial will evaluate the superiority of the investigational treatment (tirabrutinib maintenance therapy) over standard care (observation with placebo) in terms of progression-free survival in patients with newly diagnosed primary central nervous system lymphoma (PCNSL) who have achieved complete response (CR or CRu) following induction therapy with high-dose methotrexate (HD-MTX)-based chemotherapy and have not undergone consolidative whole-brain irradiation. Participants will: Take protocol drug tirabrutinib or a placebo every day until disease progression or experience of unacceptable toxicity. Visit the clinic once every 4 weeks for checkups and tests, as well as protocol drug prescription.

Conditions

  • Primary Central Nervous System Lymphoma

Interventions

  • TirabrutinibDrug

    Tirabrutinib (480 mg) taken orally daily at fasting condition

  • PlaceboDrug

    Placebo taken orally daily at fasting condition

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) based on independent review committee (IRC) assessmentTime frame: From the date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 78 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyorin University Hospital

    Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.